Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Edwards Lifesciences Corporation (NYSE:EW) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and three have given a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $87.0556.

Several analysts recently weighed in on EW shares. Truist Financial upped their price target on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. Robert W. Baird increased their target price on Edwards Lifesciences from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, July 25th. Mizuho increased their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Finally, Canaccord Genuity Group increased their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a research note on Friday, July 25th.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $74.02 on Friday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $43.46 billion, a P/E ratio of 10.65, a PEG ratio of 3.61 and a beta of 1.05. The stock’s 50 day moving average is $78.09 and its 200 day moving average is $76.10. Edwards Lifesciences has a twelve month low of $64.89 and a twelve month high of $83.00.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities research analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. CHICAGO TRUST Co NA lifted its position in shares of Edwards Lifesciences by 2.9% during the 3rd quarter. CHICAGO TRUST Co NA now owns 12,004 shares of the medical research company’s stock valued at $934,000 after buying an additional 341 shares in the last quarter. Trust Point Inc. bought a new stake in Edwards Lifesciences during the third quarter valued at about $687,000. Amiral Gestion raised its holdings in Edwards Lifesciences by 156.4% during the third quarter. Amiral Gestion now owns 282,795 shares of the medical research company’s stock valued at $21,993,000 after acquiring an additional 172,481 shares during the period. Wedmont Private Capital raised its holdings in Edwards Lifesciences by 3.8% during the third quarter. Wedmont Private Capital now owns 12,545 shares of the medical research company’s stock valued at $962,000 after acquiring an additional 455 shares during the period. Finally, Czech National Bank raised its holdings in Edwards Lifesciences by 4.0% during the third quarter. Czech National Bank now owns 149,112 shares of the medical research company’s stock valued at $11,596,000 after acquiring an additional 5,727 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.